Eurofins Biomnis code

IPHEN

Synonyms

• Acute leukemia
• ALL
• AML
• Blast cell phenotype
• Blasts
• CLL
• Flow cytometry or circulating lymphocytes
• Leukemia chronic myelomonocytic
• LMMC
• Lymphocyte Immunophenotyping
• Lymphocyte phenotyping
• Monocytes
• Plasmocyte immunophenotyping
• Score matutes
• [To be translated]
• Typing of the Lymphoproliferative Disorders

Specialty

Oncology- haematology

Clinical significance

Immunophenotyping is used to diagnose and monitor haematological malignancies. It is used to characterise the cell line involved. Depending on the clinical context and the results of the CBC, the laboratory determines the panel of antibodies to be tested, specific to the cell type of interest: lymphocytes, plasma cells or blasts. 1/ study of lymphoid proliferations: the panel of antibodies tested can be used to identify chronic B lymphoid proliferations (CLL, prolymphocytic leukaemia, mantle cell lymphoma, lymphoma villeux, follicular lymphoma), T lymphocyte proliferations or NK lymphocyte proliferations. Markers used for lymphoproliferative syndromes (non-exhaustive list): CD19, CD20, CD23, CD22, FMC7, CD10, CD5, CD3, CD4, CD8, kappa and lambda chains. These can be used to calculate the Matutes score if a pathological population is identified. 2/ study of blasts: the panel of antibodies used to identify blasts (CD34+ cells in particular) and determine their lineage (B, T or myeloid), for the diagnosis and monitoring of acute leukaemias. This panel is also used in the context of myelodysplastic or myeloproliferative syndrome (to help quantify blasts). 3/ Plasma cell study: this analysis is carried out in the context of myeloma or to investigate a monoclonal peak. As a reminder, plasma cells are not usually found in the blood but only in the bone marrow. They are identified by specific markers (CD38+/CD138+). The panel used makes it possible to determine their clonality and quantify them (the myelogram remains the reference technique for counting plasma cells). 4 / Study of blood monocytes (CD14/CD16 profile): this analysis is carried out in the context of suspected chronic myelomonocytic leukaemia (CMML). In normal blood, three monocyte subtypes have been identified on the basis of their CD14 and CD16 expression levels: classical monocytes or MO1 (CD14+/CD16-), intermediate monocytes or MO2 (CD14+/CD16+), and non-classical monocytes or MO3 (CD14low/CD16+). In CMML, the proportion of classical monocytes is greater than or equal to 94% (Selimoglu-Buet D et al. Blood 2015). According to the WHO diagnostic criteria, this analysis does not replace the myelogram.

Preanalytics

•  :
• EDTA whole blood 1 tube 5 mL(tubes with gel separators are prohibited) + 1 unstained blood smear. Bone marrow collected on EDTA 1 tube > 0,5 mL (tubes with gel separators are prohibited) + 1 unstained medullary smear
•   Ambient temperature

• A tube specifically for this analysis : No

Further information

Cannot be performed on CSF
The sample must reach us WITHOUT FAIL within 24 hrs of sampling.
Use the specific request form B8-INTGB: Malignant blood disorders
For monocyte immunophenotyping, the sample cannot be analyzed beyond 48 hours. Please do not collect on Fridays or the day before public holidays.
ALWAYS attach the last blood/platelet count results.
Monocyte immunophenotyping is not possible on bone marrow
No large tubes (only tubes up to 5ml)

Documents to download

• Specific Test Request Form (B8-INTGB)

Methodology

Flow Cytometry

Turnaround time

Turnaround time : according to clinical details : acute hemopathies : 2 days; other hémopathies : 5 days